UK pharmaceutical and medical device regulation, read for one question only: what does it change for a company selling abroad. Four items of substance this week, and a list of the things that did not move.
The MHRA is consulting on its statutory fees for 2026. Standard export certificates for medicines go from £82 to £104, and the two-working-day urgent service from £182 to £231 — described in the consultation as a targeted increase above indexation for higher-value services. The medical device post-market surveillance registration fee moves from £300 to £511 per chargeable category, with a partial subsidy retained rather than full cost recovery. A headline indexation of 8.93% is applied to 180 fees. All of it is proposed to take effect on 1 April 2027.
What it changes for exportersIf you order export certificates in any volume, your 2027 cost base moves before your prices do — and the certificate is often the document that satisfies free-sale requirements in the markets that do not recognise a UK conformity mark. The consultation is still open, and most respondents to an MHRA fees consultation are domestic. A response that explains what the certificate is actually used for abroad is unusually likely to be read.
Canada was the last member to ratify, so the United Kingdom now has full access across the bloc. The government puts over 99% of current UK goods exports to members in scope for zero tariffs, and business visitor stays in Canada extend from ninety days in any six months to six months.
What it changes for exportersCheck your own commodity codes rather than the headline. The announcement makes no mention of pharmaceuticals, medical devices or healthcare goods — the health-specific element sits in the MHRA's export certificate guidance, updated in July, not in the trade announcement. Treat this as a general tariff and mobility change that may or may not touch your lines.
Three amendments were tabled, of which one matters here: powers under which devices placed on the Great Britain market through a domestic route could in future require a licence issued by the MHRA, rather than relying on third-party conformity assessment. The MHRA states plainly that this introduces no immediate change and that any regime would follow further policy work, public consultation, impact assessment and parliamentary scrutiny.
What it changes for exportersNothing this year, and it should not be reported as a done deal. But if you are setting a three to five year regulatory strategy, note the direction: a domestic licensing model would move Great Britain further from the conformity-assessment framework that most foreign reference lists were written around. That gap is already the reason a UKCA certificate buys you little abroad.
Four recommendations: staged authorisations, described in the commission's own analogy as learner plates — deploy under supervision with tight controls before fuller authorisation; continuous real-world monitoring across the lifecycle rather than a single point of approval; a publicly searchable safety register of AI-enabled devices including adverse incidents, with patients told when AI is used in their care; and stronger enforcement powers for the regulator.
What it changes for exportersIf you sell AI-enabled devices, a staged UK authorisation would sit awkwardly against the EU's combination of the medical device rules and the AI Act. The practical question is what you would then be able to present abroad: a conditional or staged UK approval is a weaker document in a reliance-based market than a completed one.
The authority launched a tool that lets field inspectors photograph packaging or labelling, extract the data automatically, cross-reference it against approved regulations and standards, and return an indicative result in six to twenty seconds. Initial rollout covers pharmaceuticals and cosmetics, with medical devices and food in later phases. The stated aim is strengthening safety checks on imported and circulating products at points of entry.
What it changes for exportersLabelling risk at the Saudi border rises immediately for pharmaceuticals. A discrepancy between what was approved and what is printed — a changed ingredient statement, an outdated address, an Arabic panel that does not match the English — used to depend on which inspector opened which carton. It is now a twenty-second automated check. Devices are not in the first phase, but that is a matter of timing.
Two items: the border verification tool above, and an enforcement action over non-compliant advertising claims for a pain-relief device on 6 September.
Nothing published in the window. The regulator's latest news item is dated 27 August.
Nothing published between 27 August and 10 September.
Not verifiable this week. The Turkish announcements pages would not serve to an automated check, the Egyptian news centre returns no article content, and the Nigerian newsroom carries no dated September items — its own footer still reads "content current as of January 2024". We will not report absence of news as absence of change, so these three are marked unchecked rather than quiet.
One story circulating in the Nigerian press on 6 September, framed as a new policy cutting drug imports by 70%, is on reading a progress report on a measure introduced in 2019. We have left it out on that basis. The genuinely useful background is that the restricted-import list has grown from nine products in 2020 to thirty-six.
Checked this week and unchanged. In a field where silence is usually mistaken for movement, this list is half the value of a digest.
| Item | Last changed |
|---|---|
| UK approved bodies list | 17 July 2026 |
| Outcome of the consultation on recognising CE marking indefinitely in Great Britain | Closed 10 April 2026, outcome still unpublished |
| The pending pre-market medical devices instrument, covering international reliance and device identification | Implementation page last updated 12 March 2026; no laying date published |
| Statutory instruments on medicines or devices | None made in the window |
| Notices to exporters | 30 July 2026 |
| Certificate of free sale guidance for devices | 1 April 2026 |
| UK–Gulf trade agreement | Concluded 20 May 2026 — still not signed, not ratified, not in force |
It renders with a current date and is labelled a beta version, but the newest circular listed on it is dated July 2022. An exporter checking it would reasonably conclude that nothing has changed in four years. The authority's news feed, by contrast, is current — the border verification tool above was announced there on 1 September.
Worse, a circular from April 2021 on interim marketing authorisation procedures — marked inactive since June 2024 — ranks highly in search and reads as if it were live guidance.
What to do: use the news feed for that authority, not the English circulars index, and check the Arabic version before concluding a circular is the latest. This is the sort of thing that makes a provider's citation wrong while looking impeccable.
Every item is taken from the authority's or government's own publication and dated. Where only a secondary source exists we say so, and where we could not reach an official source we mark the market unchecked rather than guessing. Nothing is included to fill a section: this week produced four substantial items, so this digest has four.
We also exclude compiled press-release feeds and consultancy content dressed as news. One widely circulated "weekly brief" covering this same window contained no item from any of the regulators above, and no sourcing at all.
One page a week, by email, free. Reply once to stop and you are removed the same day.
Email to subscribe